Animals often suffer unexpected drug reactions or treatment failures that go unnoticed until serious harm occurs. Without early detection, these problems escalate — compromising animal welfare, food safety, and even contributing to antimicrobial resistance. The importance of veterinary pharmacovigilance is exactly in preventing such avoidable risks by continuously monitoring medicines, so issues are caught early, and interventions can be made early on.

Why does the importance of veterinary pharmacovigilance go beyond regulatory compliance?

Veterinary pharmacovigilance isn’t just about fulfilling legal requirements — it’s about ensuring animal health outcomes are optimized in real settings. The importance of veterinary pharmacovigilance lies in identifying adverse drug reactions, off-label unexpected effects, or other interactions early, so treatments can be adjusted or withdrawn. At veterinary pharmacovigilance, our services include establishing and maintaining pharmacovigilance system master files, reporting suspected adverse events, signal management, benefit risk reports and staff training to support these proactive measures.

Under Regulation (EU) 2019/6, which came into full force in January 2022, any veterinary medicinal product (VMP) placed on the EU market must undergo continuous safety monitoring, including maintaining a pharmacovigilance system and master file. The regulatory changes also emphasize signal management throughout the product life cycle, replacing periodic updates with a system that demands constant vigilance.

Beyond compliance, this system delivers real benefits: animals receive safer medicines, fewer unexpected adverse events, and veterinary practitioners can rely on clearer, evidence-based guidance. The importance of veterinary pharmacovigilance extends well beyond ticking regulatory boxes — it’s about safeguarding welfare, optimizing therapeutic use, and preventing avoidable harm.

How does veterinary pharmacovigilance improve early detection of adverse drug reactions in animals?

Rapid detection of adverse events(AEs) is critical to protecting animal health. The importance of veterinary pharmacovigilance shows when real-world data from veterinarians, animal owners, pharmaceutical firms, and regulators are collected, shared, and analysed in near real time. At Billev Pharma East, we help clients set up systems to capture those reports, establish signal-detection workflows, and integrate learnings back into product safety or usage guidelines.

Key EU legislation — especially Regulation (EU) 2019/6 — requires marketing authorisation holders to monitor safety continually, not just through periodic summaries but via mechanisms like EudraVigilance Veterinary (EVVet), the Union Pharmacovigilance Database, and signal-management modules in Veterinary Good Pharmacovigilance Practices (VGVP). These systems allow suspected adverse events to be reported without undue delay, literature to be scanned, and safety signals to be validated to assess risk vs. benefit. For example, EMAs VGVP guidelines mandate procedures for collecting, recording, and analysing AEs to ensure that new or unexpected issues are rapidly escalated.

Benefits include reducing the duration and severity of adverse effects in treated animals, preventing recurrence in similar cases, adjusting treatment protocols or dosages earlier, and sometimes discovering species-specific safety concerns that might otherwise go unnoticed. Ultimately, this early detection driven by the importance of veterinary pharmacovigilance translates into better animal welfare, reduced mortality or morbidity, and more confidence in veterinary medicines.

What link exists between pharmacovigilance and controlling zoonotic disease risks?

The importance of veterinary pharmacovigilance becomes especially clear when considering zoonotic diseases — those illnesses transmissible between animals and humans. By monitoring safety and efficacy of veterinary medicinal products post-market, pharmacovigilance systems help detect not only adverse drug reactions but also patterns of misuse or suboptimal treatment that may foster emergence or spread of zoonotic pathogens.

For example, the misuse of antibiotics in animals (e.g. inappropriate dosage, off-label use, prophylactic overuse) can lead to antimicrobial resistance (AMR). Resistant bacteria may cross from livestock or companion animals to humans through direct contact, the food chain, or environmental contamination. EMA’s work on antimicrobial resistance emphasises that veterinary antimicrobial consumption must be monitored and minimized, to reduce the risk to both animal and public health. Also critical is the oversight of drug residues and withdrawal periods. If withdrawal periods are not respected, residues may persist in meat, milk, or eggs consumed by humans, potentially contributing to low-dose exposure to drug compounds, which in turn may encourage resistance or allergic reactions. Veterinary pharmacovigilance systems mandated by Regulation (EU) 2019/6 demand continuous safety monitoring, including environmental impact, off-label use, and residue controls.

How signal detection in veterinary pharmacovigilance helps prevent zoonotic spillover

A key mechanism by which veterinary pharmacovigilance helps control zoonotic disease risk is signal detection — identifying patterns or clusters of adverse events, treatment failures, or unexpected drug behavior across populations or species. The earlier a concerning signal is recognized, the sooner corrective measures can be taken (e.g. changing drug use policy, restricting certain antimicrobials, updating dosing guidelines, or enhancing withdrawal time enforcement).

EU guidelines (VGVP – Veterinary Good Pharmacovigilance Practices) include a specific module on signal management for veterinary medicinal products. Marketing-authorisation holders and competent authorities are required to collect suspected adverse event reports, analyse them systematically, compare across species, evaluate off-label use, and monitor literature/publications for emerging safety issues.

Moreover, risk assessment guidelines specifically for antimicrobial veterinary medicinal products (food-producing species) require applicants to evaluate the risk to public health due to AMR as part of the authorisation process. This means that signal detection doesn’t just respond to events, but is ideally predictive or preventive.

How does veterinary pharmacovigilance strengthen food safety and consumer confidence?

Food safety depends heavily on ensuring that veterinary medicines do not leave harmful residues, and that withdrawal periods are correctly observed. A strong pharmacovigilance framework ensures that any safety signals—whether from clinical use, laboratory testing, or reports of residue violations—are identified, communicated, and acted upon swiftly. When consumers hear of recalls or residues exceeding legal limits, damage to trust can be serious.

By complying with regulations, applying VGVP guidelines, and using databases like EudraVigilance Veterinary to monitor suspected adverse events or residue issues, producers can assure consumers that their products meet both safety and ethical standards. Transparency in communication and corrective actions also help consumer to enhance their confidence in both food products and in regulatory oversight.

Why should veterinarians and farmers actively participate in pharmacivigilance reporting?

Veterinarian’s and farmer’s observations are essential data sources for pharmacovigilance: they interact with their animals daily and often are first to spot adverse effects or unexpected treatment failures. Without their reports, many safety signals might never emerge. Active participation means that adverse event (AE) reports are comprehensive, including from diverse breeds, species and contexts; this breadth allows for detection of safety issues that may depend on species, regional practices or environmental factors.

Moreover, when vets and farmers report, they can influence product labelling or usage guidelines based on real-world evidence. They help refine dosage, identify breed-specific sensitivities, or detect interactions. Their input ultimately improves treatment outcomes, reduces livestock losses, and enhances animal welfare.

Participation also builds awareness which is crucial forunderstanding what constitutes an adverse event, recognising lack of efficacy, knowing where and how to report. When that becomes routine, reporting increases and the pharmacovigilance system becomes stronger and more trustworthy.

What motivates veterinarians and farmers to report, and what are the concrete benefits?

Veterinarians and farmers may wonder: why go through the effort of reporting suspected adverse events? The importance of veterinary pharmacovigilance lies not just in fulfilling obligations, but in real, tangible benefits for animal health, treatment outcomes, farm productivity, and even legal compliance.

Motivations and benefits:

• Improved treatment safety and effectiveness: When vets and farmers report suspected adverse reactionsit helps build a database that reveals patterns. Over time, this data can lead to safer dosages, better treatment protocols or identification of breed- or species-specific sensitivities. (VGVP, EMA).
• Faster regulatory responses & risk mitigation: Thanks to systems like EudraVigilance Veterinary, reports trigger signal detection and signal management under Regulation (EU) 2019/6. That means authorities can issue warning updates, require label changes, adjust withdrawal periods, or even suspend medicines when risks are deemed too high. Farmers benefiting from early mitigation avoid losses from treatment failures or adverse effects.
• Contribution to animal welfare and trust: Reporting shows care and responsibility. Producers who are proactive in safety reporting help ensure healthier livestock or companion animals. Public confidence in animal products (food, dairy, etc.) and veterinary medicines increases when the industry behaves transparently.
• Legal & regulatory alignment: In many jurisdictions, including under EU law, marketing-authorisation holders have obligations to maintain pharmacovigilance systems and report suspected adverse events. Veterinarians may have legal requirements or at least expectations via professional bodies to report. Not doing so can risk non-compliance or missing early warnings. VGVP modules define collection and recording of suspected adverse events as core elements.

By actively participating, veterinarians and farmers become guardians of the whole system: they help ensure that the importance of veterinary pharmacovigilance translates into safer medicines, reliable treatment outcomes, reduced losses, and better welfare for animals—and ultimately benefit the entire food chain and public health.

How will digital tools and data sharing shape the future of veterinary pharmacovigilance?

The rise of digital innovation holds great promise for enhancing the importance of veterinary pharmacovigilance by improving speed, precision, and reach in monitoring the safety of veterinary medicines.

Firstly, the European regulatory network is pushing forward with its Veterinary Big Data strategy (2022-2027). The EMA and Heads of Medicines Agencies (HMA) are gathering real-world data (from farm management systems, animal health records, environmental monitoring, etc.) into interoperable systems like the Union Product Database, and increasingly using tools that allow analysis of large datasets to spot trends or risks.

Secondly, data-processing platforms such as EudraVigilance Veterinary (EVVet) allow marketing authorisation holders and authorities access to networks where suspected adverse event reports can be submitted, stored, analysed, and queried in a more automated way. These platforms facilitate signal detection, submitting of anunual statments, quicker recognition of safety issues, and even proactive risk management.

Thirdly, digital reporting tools (apps, online portals, integrated farm management software) reduce barriers for veterinarians and farmers to submit adverse event data. This helps address under-reporting, improves data completeness, and helps collect more species- or region-specific data. Some regulatory guidance (VGVP) explicitly mentions the usefulness of digital tools and email or online platforms for communication and data collection.

Lastly, data sharing across stakeholders (veterinary practices, regulatory bodies, pharmaceutical companies) supported by secure, interoperable systems will enable faster exchange of safety signals, align global standards, and amplify the power of analysis. As data volume and tool sophistication grow, the importance of veterinary pharmacovigilance will increasingly become central to preventing harm, guiding policy (e.g. antimicrobial resistance), and ensuring both animal and public health.

Sources: 1 – European Medicines Agency. (2021, August 2). Guideline on veterinary good pharmacovigilance practices (VGVP) – Module: collection and recording of suspected adverse events for veterinary medicinal products, 2 – European Medicines Agency. (2022, January 28). Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6) – Updated rules for authorisation and use of veterinary medicines in the European Union, 3 – European Medicines Agency. (2023). Signal management (veterinary medicines) – VGVP guideline, Module: Signal Management, 4 – European Medicines Agency. (n.d.). Antimicrobial resistance in veterinary medicine, 5 – European Medicines Agency. (2021). Guideline on the assessment of the risk to public health from antimicrobial resistance due to use of an antimicrobial veterinary medicinal product in food-producing animal species.